« Back to Record
Citation APA

Awada, A., Bachelot, T., Goswami, C., Deo, S., Bose, R., Wong, A., Xu, F., Yao, B., Bryce, R., Carey, L. L., Colomer, R., Inoue, K., Bondarenko, I. I., Badwe, R., Demetriou, G., Lee, S. C., Mehta, A. A., & Kim, S.-B. (2016). Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. JAMA oncology, 2(12), 1557-1564. doi:10.1001/jamaoncol.2016.0237


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/247836

Awada, A., Bachelot, T., Goswami, C., Deo, S., Bose, R., Wong, A., Xu, F., Yao, B., Bryce, R., Carey, L. L., Colomer, R., Inoue, K., Bondarenko, I. I., Badwe, R., Demetriou, G., Lee, S. C., Mehta, A. A., & Kim, S.-B. (2016). Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. JAMA oncology, 2(12), 1557-1564. doi:10.1001/jamaoncol.2016.0237